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Abstract
Studying the dysregulation of expression of glutamate receptors is crucial to 
better understand the mechanisms associated with cognitive disabilities in Down 
syndrome (DS) patients. By using data of microarray experiments previously 
deposited in GEO Dataset, we studied the expression of 26 glutamate receptor genes 
in DS brain samples since prenatal to adult age in several brain structures. Overall, 
our results showed a complexity in the expression of the genes which were depen-
dent mainly on the brain structure analyzed; especially, the hippocampus showed a 
different expression pattern. While in the general brain analysis the overexpressed 
genes were GRIN3A and GRIN2C, higher expression levels of GRM1, GRID2, and 
GRIK1 gene receptors were recorded in hippocampus. Our results suggest that the 
glutamatergic system in association with other neurotransmitter systems in the 
human brain would associate with glutamatergic receptor alterations to bring upon 
synaptic changes and cognitive deficits in DS models.
Keywords: glutamatergic system, gene expression, Down syndrome, brain, 
bioinformatics
1. Introduction
Down syndrome (DS) or trisomy 21 is the leading cause of genetically defined 
intellectual disability, developmental brain abnormalities, and congenital birth 
defects. The phenotypical features of this syndrome affect almost all body systems, 
including neurodevelopment and cognitive aspects [1, 2]. Brains of individuals with 
DS show decreased volume and reduced neuronal density in diverse areas includ-
ing the cortex, hippocampus, and cerebellum [3–7], leading to delayed cognitive 
progress in infancy and childhood and mild-to-moderate intellectual disability 
[8–11]. Also, during adulthood, there is a loss of cognitive abilities and the develop-
ment of Alzheimer’s disease (AD) by the fourth decade of life [12, 13]. Glutamate is 
the principal and main excitatory neurotransmitter in the body [14–16]. Glutamate 
receptors are classified into metabotropic—G-coupled protein receptors—and 
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ionotropic—ligand-gated ion channels [17–26]. Many studies have agreed that a 
major function of glutamate receptors is the modulation of synaptic plasticity, 
which is the ability of neurons to change its connections in response to a stimuli; 
this mechanism is thought to be vital for memory and learning processes. An 
increase or decrease in the number of ionotropic glutamate receptors on a postsyn-
aptic cell may lead to long-term potentiation or long-term depression of that cell, 
respectively [27–30].
According to Tan et al. [31], there is evidence that reduction in hippocampal 
glutamate concentrations is associated with improved cognitive function by modu-
lating glutamatergic neurotransmission in non-DS people with AD. Also, murine 
models of DS suggest that there is an imbalance between hippocampal inhibitory 
and excitatory inputs [9, 24], changes in the levels of the glutamate transporter and 
vesicular glutamate transporter 1 (VGLUT1) [25], and impairments in signaling 
mechanisms downstream of the N-methyl-D-aspartate (NMDA) receptor [26]. In 
this context, it can be put into consideration that malfunctions in the glutamate 
metabolism and the glutamatergic system are major contributors to cognitive 
abnormalities.
In recent studies, it has been shown that patients with DS present a diminution 
of glutamate and glutamatergic synapses. In the research made with mice by Kaur 
et al. [32], the results indicated a downregulation of hippocampal glutamate associ-
ated with behavioral impairments and intellectual disabilities. In this context, our 
study aimed to analyze the differential expression of 26 glutamate receptor genes 
in DS brain samples from prenatal patients to adult age in several brain structures. 
Overall, our result showed the complexity in the expression of the 26 glutamate 
receptors encoding genes. Also, a general overexpression in brain samples of 
GRIN3A and GRIN2C, and higher expression levels of GRM1, GRID2, and GRIK1 in 
hippocampus, in comparison with some structures of brain cortex. We hypothesize 
that disruption of glutamatergic brain gene expression would be a crucial early step 
in the pathogenesis of cognitive disability in DS.
2. Glutamate receptors and DS
Glutamate is known to be the main excitatory neurotransmitter in the brain and 
under normal physiological conditions, mediates learning and memory, as well as 
other integrating brain functions of higher order; however, it is also known that 
the pathological signaling of glutamate contributes to neuronal cell death. This 
neurotransmitter is released in the synapse after the depolarization of the presyn-
aptic neurons, and it is eliminated by means of the GLT transporter in astrocytes, 
in normal physiological conditions, glutamate elimination being rapid and neu-
roprotective [33]. Glutamate has action on ionotropic (iGluR) and metabotropic 
(mGluRs) receptors. The ionotropic GluRs are ion channels (voltage sensitive), 
integral membrane proteins composed by four large subunits that form a central ion 
channel pore [34]. Glutamate receptor subunits are modular structures that contain 
the following domains: the extracellular amino-terminal domain (ATD), the extra-
cellular ligand-binding domain (LBD), the transmembrane domain (TMD), and an 
intracellular carboxyl-terminal domain (CTD) [34].
These receptor subunits are proteins assembled into heterotetrameric or 
homotetrameric receptors, including the N-methyl-D-aspartate receptor (NMDA) 
consisting of the subunits GluN1, GluN2A, GluN2B, GluN2C, GluN2D, GluN3A, 
and GluN3B, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
with the subunits GluA1, GluA2, GluA3, and GluA4, and the Kainate receptors with 
the subunits GluK1, GluK2, GluK3, GluK4, and GluK5 that function as mediators of 
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the rapid synaptic responses to glutamate, contrary to what happens with mGluRs 
where their activation by glutamate is sensitive to ligand binding and produces 
slower and longer modulating alterations in synaptic activity [33, 35–37]. NMDA 
receptors are present in high density within the hippocampus and the cerebral cor-
tex performing fundamental physiological and pathophysiological functions in the 
central nervous system [38], among which learning, memory, brain plasticity, and 
recovery of injuries stand out. In these brain structures, differential expression of 
these receptors is evidenced, where a change in their dynamics could contribute to 
changes in cognitive and synaptic function [39]. When treated in conjunction with 
AMPA, they are attributed an important role in plasticity and synaptic transmission 
in many postsynaptic membranes [35, 40], with the latter receptors participating in 
protein-protein interactions with scaffolding proteins, such as PICK1 and GRIP1, 
and the TARP accessory proteins that help in AMPA receptor traffic and present 
additional targets for regulation [37].
Metabotropic glutamate receptors are members of the superfamily of G protein-
coupled receptors. There are eight mGluR subtypes divided into three groups based 
on sequence homology, G-protein coupling specificity, and pharmacological profile. 
In general, mGluRs of group I and their interacting proteins have the ability to 
function as both neuroprotective and neurotoxic and have also been implicated in 
neurodegenerative diseases, especially mGluR5 [33]. On the other hand, members 
of group II act by inhibiting neuronal responses in rats according to the studies of 
Copeland et al. [41], which has been associated with the onset of cognitive deficit, 
a characteristic that can be observed in people with DS. About this syndrome, it 
should be noted that it has been associated with an imbalance of excitatory/inhibi-
tory neurotransmitter systems, as highlighted in studies of murine with DS where 
the presence of alterations in the activity of glutamatergic neurotransmission, 
mainly affecting ionotropic receptors, an event that has also been evidenced when 
studying the overexpression of HSA21 genes in DS [42].
3. Glutamatergic system, cognition, and DS: our main approach
The glutamatergic system of the brain is one of the two major amino acid 
systems, being the GABAergic system the major one. This system is very important 
for information processing in neuronal networks of the neocortex and hippocam-
pus in particular [43, 44], which is why we decided to analyze not only the brain 
as a whole, but the hippocampus apart. Also, this brain structure has been studied 
in several articles related to DS [3, 45–47] because of the significant functional 
repercussion in memory processes and intellectual potential that follows the poor 
hippocampal development presented by individuals with DS. Because the glutama-
tergic system is key in cognition processes such as memory and learning [48, 49], 
we consider that the deregulation of the glutamate receptors could be critical in the 
pathophysiology of DS, specifically in the neurodevelopmental and neurocognitive 
defects. This can be a starting point for developing therapeutic strategies aimed to 
reduce the effects of altered brain structures in individuals with DS.
3.1 Our methodological approach
Our initial approach was to analyze the expression of glutamate receptors—
ionotropic and metabotropic—(Table A1) in DS brain samples and compare it 
to euploid controls. In order to accomplish this goal, we calculated the values of 
expression for selected genes by using the log10 transformed expression values 
of a DNA microarray experiment whose registration code and free access in the 
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GEO database was GSE59630 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE59630), previously deposited by Olmos-Serrano et al. [50], which 
fitted the statistical significance sample size to obtain trustable information about 
the functional neurogenomics in DS. The microarray experiment selected included 
gene expression data of 47,000 probes from 58 postmortem brain samples of DS 
patients and 58 postmortem brain samples of healthy controls classified by gender 
(25 from females and 33 from males of each condition), age (from 16 prenatal 
weeks to 42 years old), and in 11 structures: dorsolateral prefrontal cortex (DFC), 
visual cortex (V1C), cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral 
frontal cortex (VFC), inferior temporal cortex (ITC), hippocampus (HIP), medial 
frontal cortex (MFC), somatosensory cortex (S1C), inferior parietal cortex (IPC), 
and superior temporal cortex (STC).
3.2 Functional analysis
The software Cytoscape 3.6 [51] was used for visualizing and analyzing the 
protein-protein interaction network among the selected human glutamate receptors 
encoding genes. We use the BIOGrid database to obtain protein interaction data 
of each one of the genes evaluated. Biological Networks Gene Ontology plugin—
BiNGO tool—[52] was used to search in which gene ontology (GO) categories are 
significantly overrepresented in a set of genes. A hypergeometric test was applied 
to determine which were the significantly represented categories (p-value <0.05); 
significant values were adjusted using the Bonferroni family wise error rate correc-
tion [53]. From network analyzer plugin of the Max Planck Institute Informatik, 
network topology parameters were calculated. Moreover, a genetic interaction 
network was made in GENEMANIA (https://genemania.org/).
3.3 Z-score transformation
Log2 data for each gene in the DNA microarray experiment was log10 trans-
formed and then used for the calculation of Z score [54]. Z scores were calculated 
by subtracting the mean log gene intensities (within a single experiment) from the 
log intensity data for each gene, and dividing that result by the SD of all measured 
log intensities, according to Eq. (1):
Z-score transformation:
  Z − score =   
 (Log intensity of G − mean log intensity G…Gn) 
    ___________________________________________________ 
Standard Deviation log G…Gn
 (1)
All Z-score values were normalized on a linear scale −3.0 < 0 > +3.0. In it, the 
corresponding gene is overexpressed if the value of Z-score is greater than zero and 
on contrary is under-expressed if its value is negative.
3.4 Multivariate statistical analysis
Nonparametric analyses for comparing median values of Z-score were per-
formed among gender and age variables between DS patients and healthy control. 
Wilcoxon signed-rank test was used to calculate the differences between medians 
of two samples. Hierarchical clustering analysis (HCA) was selected as a method 
of cluster analysis that seeks to build a hierarchy of clusters [55]. To perform the 
HCA, Euclidean distance was used as a measure of distance between DS and control 
samples of Z-score values in several structures of brain cortex; p < 0.05 was defined 
as a threshold. Moreover, principal component analysis (PCA) was employed as 
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a computational procedure for the classification of multiclass gene expression 
in brain cortex structures between DS and control samples per sex and age. All 
analyses were run in SPSS program version 22 [56].
4. Our results
4.1 Protein-protein interaction (PPI) network and gene interactions
The PPI network made in Cytoscape 3.6 with all ionotropic and metabotropic 
receptors had 142 nodes and 3 connected components (Figure 1). The proteins 
encoded by GRIA2 and GRIN2B had the highest amount of interactions (33 and 
30, respectively). GRIA2 gene encodes a subunit of the family of glutamate AMPA 
receptors; these types of receptors mediate fast excitatory synaptic transmission. 
GRIN2B is also a subunit but, in this case, of a NMDA receptor which are involved 
in brain development, synaptic plasticity, learning, and memory. The malfunction 
of these two genes has been previously associated to neurodevelopmental disorders 
characterized by intellectual disability and delayed development of speech and 
motor skills [57–59]. Here, it is important to highlight that the many connections 
they have among the glutamatergic system make them key proteins in the brain 
protein homeostasis. Among the biological processes ontology categories associated 
to the network, there was synaptic transmission (P-value Bonferroni 6.44E-17) and 
transmission of nerve impulse (P-value Bonferroni 1.20E-15).
On the other hand, the gene interaction network made in GENEMANIA showed 
that the physical interactions with the highest weight are GRIN2A-GRIN1 (9.40E-01), 
CACNG2-GRIA1 (8.66E-01), and GRIK1-GRIK2 (8.35E-01). The gene GRIN2A encodes 
a subunit of a subset of NMDA receptors called GluN2A, mainly expressed in regions 
in the brain involved in speech and language; this gene is consistently referred to in 
the literature as associated with speech disorders such as impaired intelligibility of 
Figure 1. 
PPI network made with glutamate receptors in Cytoscape 3.6. The receptors analyzed in this study are shown in 
red; the interactors are shown in yellow.
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conversational speech [60]. GRIN1, on the other hand, also encodes a subunit of NMDA 
receptors called GluN1, which, along with other members of this superfamily, plays a 
key role in memory and learning. According to Chen et al. [61], several mutations on 
this gene have been associated with neurodevelopmental disorders such as epilepsy, 
causing in some patients hypotonia and facial dysmorphisms. GRIK1 and GRIK2 
encode subunits of the kainite family of glutamate receptors, associated with behavior 
according to the GWAS Catalog (https://www.ebi.ac.uk/gwas/) and with intellectual 
disability [62].
4.2 Temporal and spatial gene expression in postmortem brains of DS patients
According to the temporal gene expression analysis made, there were no signifi-
cant differences among the DS brain samples and the control group (Figure 2). This 
is contrasting to the results obtained in other studies focused on mice like the article 
published by Zhao et al. [63] where they found a difference between older and 
younger organisms when measuring the expression of glutamate receptors; in their 
experiment, they found that NMDA receptor functions, receptor subunit composi-
tion, and/or the environment in which the receptor interacted were not the same in 
the old mice as in younger mice which may contribute to the memory decline seen 
during aging. Also, there is a study made on embryo chicks and 1-year-old chicks by 
Batista et al. [64] where they found that AMPA receptors exhibit temporal expres-
sion changes during tectal development of chicks that are compatible with such a 
role for glutamate. All the glutamate receptor subunits tested in that experiment—
GluR1, GluR2/3, and GluR4—showed an early expression suggesting some function 
in neurogenesis and migration.
The analysis of gene expression along the different brain structures (Table 1)  
showed an overexpression of the genes Glutamate Ionotropic Receptor NMDA 
Type Subunit 2C (GRIN2C) (Z-ratio 2.61) and the Glutamate Ionotropic Receptor 
NMDA Type Subunit 3A (GRIN3A) (2.94). GRIN2C encodes a subunit of an NMDA 
receptor, which is a subtype of ionotropic glutamate receptor involved in excitatory 
neurotransmission and in neuronal cell death. On the other hand, GRIN3A also 
encodes a subunit of a NMDA receptor and its deficit increases spine density and 
initiates synapse maturation and memory consolidation in early postnatal neurode-
velopment; both of these genes have been previously associated with schizophrenia. 
Figure 2. 
Z-score of glutamate ionotropic receptors per age-range of control and DS brain samples. Prenatal: 16–22 pre-
gestational weeks, 8 months to 1 year; teens: 12–18 years; and adults: 19–42 years.
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According to Ohi et al. [65], GRIN3A expression levels in the dorsolateral prefrontal 
cortex were elevated by approximately 30% in schizophrenia patients relative to 
controls, which suggest that aberrant enhanced GRIN3A function could be involved 
in the pathophysiology of schizophrenia and its cognitive impairments. Another 
study by Marco et al. [66] in patients with Huntington’s disease (HD) and in a 
mouse model of HD found something similar; a knockout of this gene decreased 
motor and cognitive dysfunction compared with no knockout and prevented stria-
tal atrophy and synaptic disconnection. These findings correlate with our results of 
human DS brains, leading us to propose that a similar process might take place in 
the pathophysiology of DS.
Gene symbol Z-score control Z-score DS ΔZ-score Z ratio*
Ionotropics
GRIA1 1.88 1.75 −0.12 0.93
GRIA2 2.28 2.21 −0.07 0.97
GRIA3 1.46 1.21 −0.25 0.83
GRIA4 0.97 0.79 −0.18 0.82
GRID1 0.45 0.32 −0.13 0.71
GRID2 0.71 0.76 0.05 1.07
GRIK1 0.58 0.74 0.16 1.28
GRIK2 1.36 1.36 0.00 1.00
GRIK3 0.91 0.59 −0.32 0.65
GRIK4 0.77 0.59 −0.18 0.77
GRIK5 0.91 0.85 −0.05 0.94
GRIN1 0.74 0.49 −0.24 0.67
GRIN2A 1.30 0.92 −0.37 0.71
GRIN2B 1.69 1.32 −0.38 0.78
GRIN2C 0.01 0.02 0.01 2.61
GRIN2D −0.45 −0.38 0.07 0.85
GRIN3A 0.02 0.07 0.05 2.94
GRINA 2.52 2.36 −0.16 0.94
Metabotropics
GRM1 0.29 0.20 −0.09 0.69
GRM2 0.27 −0.15 −0.43 −0.57
GRM3 1.66 1.54 −0.13 0.92
GRM4 0.28 0.33 0.06 1.20
GRM5 1.35 1.39 0.05 1.03
GRM6 −0.99 −0.96 0.03 0.97
GRM7 0.48 0.34 −0.15 0.69
GRM8 −0.52 −0.70 0.18 1.34
Log2 data for gene expression were obtained from the microarray experiment consigned in the GEO database with 
ID GSE59630, previously deposited by Olmos et al.
*Z-Ratio ≥ 1.50 is statistically significant; alpha 0.05.
Table 1. 
Differential expression values (Z-score and Z-ratio) of glutamate receptor encoding genes in the brain of 
patients with Down syndrome.
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Moreover, we decided to analyze the hippocampus apart because of its 
highly recognized importance not only in Down syndrome, but also in cogni-
tion processes, which are mainly regulated by the glutamatergic system [67]. 
Several studies have agreed that NMDA receptor (NMDAR)-dependent LTP or 
an LTP-like process in the hippocampus are the neural substrate for associa-
tive spatial learning and memory [68]. In this study, we found that this brain 
structure has some differences in gene expression when compared to the brain 
as a whole. While the general analysis of the brain showed an overexpression of 
the gene GRIN3A, at the hippocampus, we encountered an under-expression if 
this gene in DS samples. On the other hand, a gene that encodes the Glutamate 
Gene symbol Z-score control Z-score DS ΔZ-score Z ratio*
Ionotropics
GRIA1 2.15 2.25 0.10 1.04
GRIA2 2.48 2.35 −0.13 0.95
GRIA3 1.59 1.62 0.03 1.02
GRIA4 0.14 −0.07 −0.21 −0.49
GRID1 0.59 0.55 −0.04 0.93
GRID2 0.18 0.47 0.29 2.61
GRIK1 0.37 0.60 0.23 1.62
GRIK2 1.35 1.20 0.15 0.88
GRIK3 0.58 −0.19 −0.77 −0.32
GRIK4 0.96 0.95 −0.01 0.99
GRIK5 1.14 1.22 0.08 1.07
GRIN1 0.74 0.49 −0.25 0.67
GRIN2A 1.28 1.15 −0.13 0.90
GRIN2B 1.74 1.73 −0.01 0.99
GRIN2C 0.19 0.34 0.15 1.85
GRIN2D −0.56 −0.41 0.15 0.73
GRIN3A 0.35 −0.22 −0.57 −0.62
GRINA 2.40 2.28 −0.12 0.95
Metabotropics
GRM1 0.10 0.22 0.12 2.22
GRM2 0.10 −0.54 −0.64 −5.62
GRM3 1.68 1.30 −0.38 0.77
GRM4 0.12 0.05 −0.07 0.44
GRM5 1.51 1.62 0.11 1.07
GRM6 −0.96 −0.87 0.09 0.91
GRM7 0.71 0.51 −1.22 0.72
GRM8 −0.54 −0.75 −0.21 1.37
Log2 data for gene expression were obtained from the microarray experiment consigned in the GEO database with 
ID GSE59630, previously deposited by Olmos et al.
*Z-Ratio ≥ 1.50 is statistically significant; alpha 0.05.
Table 2. 
Differential expression values of glutamate receptor encoding genes in the hippocampus of patients with Down 
syndrome.
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Metabotropic Receptor 1 (GRM1) was overexpressed in the hippocampus 
(Z-ratio 2.22) as well as the Glutamate Ionotropic Receptor Delta Type Subunit 
2 (GRID2) (Z-score 2.61), the Glutamate Ionotropic Receptor Kainate Type 
Subunit 1 (GRIK1) (Z-score 1.62), and GRIN2C (Z-score 1.85). GRM1 is one 
of the most abundant mGluRs in the mammalian central nervous system and 
is present at particularly high levels in Purkinje cells [69]. There is plenty of 
evidence of its implication in diseases involving glutamatergic dysfunction and 
abnormal synaptic plasticity [70], which are known to be crucial mechanisms for 
cognitive processes. GRIK1 has also been reported as overexpressed in studies of 
DS; the study made on mice by Mazier [71] showed that GRIK mRNA levels are 
increased by more than 50% in different structures of the trisomic brain, which 
is coincidental with our findings (Table 2).
4.3  Principal component analysis (PCA) and hierarchical cluster analysis 
(HCA)
According to the PCA performed for the control samples, five principal 
components explained 80% of the cumulative variance; meanwhile, the PCA 
performed for the DS samples showed that six principal components explained 
83% of the cumulative variance. In Figure 3, we present the PCA for the two 
groups, where we found some differences in the clustering of genes when 
comparing the group samples, specifically in genes GRID2, GRM1, GRM4, and 
GRIK2 which were closely grouped in the PCA for controls. Also, even though 
the gene GRIK1 remained on the same position in both PCA, its association with 
GRIA1 changed from being separated in the control group, to be near each other 
in the DS group.
The HCA analysis produced a Heatmap that showed gene expression differences 
in the hippocampus (Figure 4), specifically in the genes Glutamate Ionotropic 
Receptor Kainate Type Subunit 3 (GRIK3) and GRIN3A which were under-
expressed in DS samples as mentioned previously. GRIK3 has not been related 
to DS in particular, but it has been widely studied for its association with schizo-
phrenia and major depression [72, 73]. Overall, the expression of the glutamate 
metabotropic receptors was especially high in the OFC in comparison to other brain 
structures.
Figure 3. 
Principal component analysis in 11 brain structures in DS brain samples and controls: dorsolateral prefrontal 
cortex (DFC), visual cortex (V1C), cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral frontal 
cortex (VFC), inferior temporal cortex (ITC), hippocampus (HIP), medial frontal cortex (MFC), 
somatosensory cortex (S1C), inferior parietal cortex (IPC), and superior temporal cortex (STC). Analyses 
were performed in SPSS v 22.0.
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5. Conclusions
The glutamatergic system is closely related to cognition as it plays a key role in 
memory, working memory, and executive functions. It has been proven in mice with 
DS that a deregulation of this system can be crucial in both the neurodevelopmental 
and neurodegenerative components of DS. DS patients have intellectual disabilities 
with individual variability in the severity of both physiological and behavioral 
phenotypes. At the core of the intellectual disabilities is the phenomenon of synap-
tic plasticity, which is a functional change in the strength at the points of commu-
nication between neurons. Our results indicate hippocampal downregulation of the 
ionotropic receptor subunit GRIN3A (NMDA family), while in the general analysis 
of the brain, this gene was overexpressed. Other genes overexpressed in the hip-
pocampus were the metabotropic receptor GRM1, the ionotropic receptor subunit 
GRID2, and the kainate receptor subunit GRIK1. This deregulation might produce 
an alteration of both presynaptic and postsynaptic dysfunction at glutamatergic 
synapses, possibly contributing to behavioral impairments in patients with DS.
In general, our results suggest the existence of a fine regulation mechanism 
of gene expression networks, which is involved in the glutamatergic synaptic 
Figure 4. 
Heat map of glutamate receptor expression of 11 brain structures in DS brain samples and controls. Green color 
represents under-expression and red overexpression: dorsolateral prefrontal cortex (DFC), visual cortex (V1C), 
cerebellar cortex (CBC), orbitofrontal cortex (OFC), ventral frontal cortex (VFC), inferior temporal cortex 
(ITC), hippocampus (HIP), medial frontal cortex (MFC), somatosensory cortex (S1C), inferior parietal 
cortex (IPC), and superior temporal cortex (STC); performed in Cytoscape 3.6 software.
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system in several structures of brain from patients with DS. We hypothesize that 
disruption of glutamatergic brain gene expression would be a crucial early step in 
the pathogenesis of cognitive disability in DS. Moreover, our results suggest that 
glutamatergic system in association with other neurotransmitter systems in human 
brain, as GABA-mediated synaptic inhibition reported in other DS studies, might 
associate with glutamatergic receptor alterations to bring upon synaptic changes 
and cognitive deficits in DS models. Thus, glutamatergic receptor gene expression 
dysfunction may play a key role in the hippocampal pathogenesis of DS.
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Supplementary information
ID Gene 
symbol
Subunit Official full name Locus
Ionotropic family
2890 GRIA1 GluA1 
(GluR1)
Glutamate ionotropic receptor 
AMPA type subunit 1
5q33.2
2891 GRIA2 GluA2 
(GluR2)
Glutamate ionotropic receptor 
AMPA type subunit 2
4q32.1
2892 GRIA3 GluA3 
(GluR3)
Glutamate ionotropic receptor 
AMPA type subunit 3
Xq25
2893 GRIA4 GluA4 
(GluR4)
Glutamate ionotropic receptor 
AMPA type subunit 4
11q22.3
2894 GRID1 GluD1 
(GluRD1)
Glutamate ionotropic receptor 
delta type subunit 1
10q23.1-q23.2
2895 GRID2 GluD2 
(GlurD2)
Glutamate ionotropic receptor 
delta type subunit 2
4q22.1-q22.2
Kainate family
2897 GRIK1 GluK1 
(GluR5)
Glutamate ionotropic receptor 
kainate type subunit 1
21q21.3
2898 GRIK2 GluK2 
(GluR6)
Glutamate ionotropic receptor 
kainate type subunit 2
6q16.3
2899 GRIK3 GluK3 
(GluR7)
Glutamate ionotropic receptor 
kainate type subunit 3
1p34.3
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ID Gene 
symbol
Subunit Official full name Locus
2900 GRIK4 GluK4 
(KA-1)
Glutamate ionotropic receptor 
kainate type subunit 4
11q23.3
2901 GRIK5 GluK5 
(KA-2)
Glutamate ionotropic receptor 
kainate type subunit 5
19q13.2
NMDA family
2902 GRIN1 GluN1(NR1) Glutamate ionotropic receptor 
NMDA type subunit 1
9q34.3
2903 GRIN2A GluN2A 
(NR2A)
Glutamate ionotropic receptor 
NMDA type subunit 2A
16p13.2
2904 GRIN2B GluN2B 
(NR2B)
Glutamate ionotropic receptor 
NMDA type subunit 2B
12p13.1
2905 GRIN2C GluN2C 
(NR2C)
Glutamate ionotropic receptor 
NMDA type subunit 2C
17q25.1
2906 GRIN2D GluN2D 
(NR2D)
Glutamate ionotropic receptor 
NMDA type subunit 2D
19q13.33
116,443 GRIN3A GluN3A 
(NR3A)
Glutamate ionotropic receptor 
NMDA type subunit 3A
9q31.1
2907 GRINA GluN3B 
(NR3B)
Glutamate ionotropic receptor 
NMDA type subunit associated 
protein 1
8q24.3
Metabotropic family group 1
2911 GRM1 mGluR1 Glutamate metabotropic 
receptor 1
6q24.3
2915 GRM5 mGluR4 Glutamate metabotropic 
receptor 5
11q14.2-q14.3
Metabotropic family group 2
2912 GRM2 mGluR5 Glutamate metabotropic 
receptor 2
3p21.2
2913 GRM3 mGluR2 Glutamate metabotropic 
receptor 3
7q21.11-q21.12
Metabotropic family group 3
2914 GRM4 mGluR3 Glutamate metabotropic 
receptor 4
6p21.31
2916 GRM6 mGluR6 Glutamate metabotropic 
receptor 6
5q35.3
2917 GRM7 mGluR7 Glutamate metabotropic 
receptor 7
3p26.1
2918 GRM8 mGluR8 Glutamate metabotropic 
receptor 8
7q31.33
Information taken from the NCBI—Genbank platform.
Table A1. 
Description of glutamate receptors encoding genes.
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